BriaCell's Bria-IMT™ Demonstrates Survival Advantage over Trodelvy® and Control Group in Metastatic Breast Cancer

Core Insights - BriaCell Therapeutics Corp. announced updated Phase 2 survival data for its lead immunotherapy candidate, Bria-IMT, in combination with an immune checkpoint inhibitor, showing a significant survival advantage in heavily pretreated metastatic breast cancer patients [1][2]. Survival Data Analysis - The Phase 2 study demonstrated that the median overall survival (OS) for triple-negative breast cancer (TNBC) patients treated with Bria-IMT plus CPI was 13.9 months, surpassing Trodelvy's 11.8 months and single-agent chemotherapy's 6.9 months [3][4][5]. - For hormone receptor-positive (HR+) metastatic breast cancer patients, the median OS with Bria-IMT plus CPI was 17.3 months, exceeding Trodelvy's 14.4 months and single-agent chemotherapy's 11.2 months [4][5]. - The study included 54 heavily pretreated metastatic breast cancer patients, with a median of six prior therapies, and no treatment-related discontinuations were reported [7]. Comparison with Established Treatments - Bria-IMT's performance in TNBC and HR+ patient subtypes outperformed established benchmarks, indicating a potential clinical impact of the novel immunotherapy [2][4]. - The survival rates at 6 months for TNBC patients were 78% for Bria-IMT plus CPI compared to 80% for Trodelvy and 56% for single-agent chemotherapy [3]. - For HR+ patients, the survival rates at 6 months were 90% for Bria-IMT plus CPI, compared to 83% for Trodelvy and 76% for single-agent chemotherapy [3]. Future Outlook - The company is looking forward to validating these findings in its ongoing pivotal Phase 3 study, which has overall survival as its primary endpoint [2][6].